{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:22:56Z","timestamp":1769858576703,"version":"3.49.0"},"reference-count":34,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.2217\/fon.14.214","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T09:46:07Z","timestamp":1411119967000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel"],"prefix":"10.1080","volume":"11","author":[{"given":"Edurne","family":"Arriola","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital del Mar,Passeig Mar\u00edtim 25\u201329, 08003 Barcelona;IMIM (Institut Hospital del Mar d\u2019Investigacions M\u00e8diques),\rDr Aiguader 88, 08003 Barcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology (ICMHO),Hospital Cl\u00ednic,\rVillarroel 170,\r08036 Barcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Artal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Hospital Universitario Miguel Servet,Av. Isabel la Cat\u00f3lica,\r50009 Zaragoza,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[{"name":"FEA Oncolog\u00eda M\u00e9dica, HRU Carlos Haya, Av de Carlos Haya s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario A Coru\u00f1a, As Xubias 84, 15006 A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Hospital Universitario Central de Asturias,Celestino Villamil s\/n,\r33006 Oviedo,\rAsturias,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari Carmen","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Oncology Nurse (ICMHO),Hospital Cl\u00ednic,\rVillarroel 170,\r08036 Barcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Garc\u00eda-Muret","sequence":"additional","affiliation":[{"name":"Department of Dermatology,Hospital de la Santa Creu i Sant Pau,\rSant Quint\u00ed 89,\r08026 Barcelona,\rSpain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"issue":"5","key":"e_1_3_2_2_1","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5","author":"Cooper WA","year":"2013","unstructured":"Cooper WA , LamDCL, O\u2019TooleSA, MinnaJD. Molecular biology of lung cancer. J. Thorac. Dis.5(Suppl 5), S479\u2013S490 (2013).","journal-title":"J. Thorac. Dis."},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4235"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.109"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.1764"},{"key":"e_1_3_2_10_1","volume-title":"50th American Society of Clinical Oncology (ASCO) Annual Meeting.","author":"Yang JC-H","year":"2014","unstructured":"Yang JC-H , SequistL VSchulerMet al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19\/L858R) Epidermal Growth Factor Receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). Presented at: 50th American Society of Clinical Oncology (ASCO) Annual Meeting.Chicago, IL, USA, 30 May\u20133June2014. Abstract 21366."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.12.002"},{"key":"e_1_3_2_12_1","unstructured":"Clinicaltrials.gov. http:\/\/www.clinicaltrials.gov (Accessed: 22May2014)"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8782"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70087-6"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0981"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i3.877"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.30"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.31"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.832755"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182773fce"},{"key":"e_1_3_2_21_1","volume-title":"38th Annual Congress of the European Society for Medical Oncology (ESMO).","author":"Yang JC","unstructured":"Yang JC , SequistL V., O\u2019ByrneKJet al. Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib. Presented at: 38th Annual Congress of the European Society for Medical Oncology (ESMO).Amsterdam, Netherlands, 27 September-1 October 2013."},{"key":"e_1_3_2_22_1","volume-title":"50th American Society of Clinical Oncology (ASCO) Annual Meeting.","author":"Geater SL.","year":"2013","unstructured":"Geater SL. LUX-Lung 6: Patientreported outcomes (PROs) from a randomized open-label, Phase III study in 1st-line advanced NSCLC patients (pts.) harbouring epidermal growth factor receptor (EGFR) mutations. Presented at: 50th American Society of Clinical Oncology (ASCO) Annual Meeting.Chicago, IL, USA, 30 May- 3June 2013."},{"key":"e_1_3_2_23_1","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 [Internet]\n. (2006). http:\/\/www.ctep.cancer.gov\/protocol\/Development\/electronic_applications\/docs\/ctcaev3.pdf (Accessed 17 March 2014)."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0263-z"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0021-0"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.7573"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.10.006"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.7542"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12082"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0365"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.038"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:01Z","timestamp":1719125041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.2217\/fon.14.214"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.214","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}